Potential Clinical Applications for Human Pluripotent Stem Cell-Derived Blood Components
Author Information
Author(s): Erin A. Kimbrel, Shi-Jiang Lu
Primary Institution: Stem Cell & Regenerative Medicine International, Marlborough, MA, USA
Hypothesis
Can human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) be used to generate functional blood components for clinical applications?
Conclusion
hESCs and iPSCs have the potential to produce various blood components, but further optimization of differentiation methods is needed for clinical use.
Supporting Evidence
- Researchers have successfully differentiated hESCs and iPSCs into specific mature blood cell types.
- hESC-derived red blood cells and platelets can perform essential functions like oxygen delivery and blood clotting.
- hESC-derived dendritic cells may be used in vaccine therapies to stimulate immune responses against cancer.
Takeaway
Scientists are trying to use special cells called stem cells to make blood components like red blood cells and platelets that can help people who are sick.
Methodology
The review discusses various methods for differentiating hESCs and iPSCs into blood components, including embryoid body formation and coculture techniques.
Limitations
Current in vitro differentiation systems need further optimization before clinical application.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website